NERVGEN PHARMA COMPLETES $10 MILLION INITIAL PUBLIC OFFERING

Vancouver, Canada. March 13, 2019 – NervGen Pharma Corp. (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has completed its initial public offering (“IPO”) of its common shares and listing as a Tier 2 company on the TSX Venture Exchange (“TSX-V”). The IPO consisted of the issuance of 10,000,000 common shares of the Company at a price of $1.00 per share for gross proceeds of $10,000,000. NervGen’s common shares are expected to commence trading on the TSX-V under the symbol “NGEN” on Friday, March 15, 2019.

Read the full article at this NervGen LINK

BioEnterprise Article March 18, 2019

This entry was posted in Ligand, Regenerative Medicine, spinal cord injury research and tagged , , . Bookmark the permalink.